First Quadrant’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

First Quadrant’s Portfolio NGM Stock Details NGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-700	Closed	-$11K	–	689
2020 Q3	$11K	Hold	700	–	–	﹤0.01%	603
2020 Q2	$14K	Sell	700 -200	-22%	-$3.82K	﹤0.01%	687
2020 Q1	$11K	Hold	900	–	–	﹤0.01%	620
2019 Q4	$17K	Hold	900	–	–	﹤0.01%	552
2019 Q3	$12K	Buy	+900	New	+$13.5K	﹤0.01%	576

Other funds holding NGM

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

RCP

Rho Capital Partners New York $20.4M AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Greenspring Associates Owings Mills, Maryland $1.48B AUM 61.93% 1-Year Est. Return

PIM

Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return

Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

First Quadrant's NGM Position: Q4 2020 in Review

First Quadrant sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q4 2020, closing a stake of 700 shares — an estimated $11K sold.

First Quadrant first reported a position in NGM in Q3 2019 and held it in 5 quarters. The position peaked at $17K in Q4 2019. 88 funds tracked by Wall St. Rank hold NGM as of Q4 2020.

First Quadrant reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
First Quadrant sold 700 NGM Biopharmaceuticals, Inc. Common Stock shares in Q4 2020, an estimated $11K.
First Quadrant first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 5 quarters.
First Quadrant's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $17K in Q4 2019.
88 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q4 2020.

Based on First Quadrant's 13F filing for Q4 2020, filed 27 Jan 2021.